Oil exploration company PTTEP has argued 15,000 Indonesian seaweed farmers who brought a class action alleging their crops were damaged after an oil spill in the Timor Sea will need to individually persuade the court to allow their claims out of time.
A litigation funder has reaped $7.5 million from the sale of a 20 per cent stake in a shareholder class action against the Commonwealth Bank of Australia over the bank’s allegedly lax money laundering compliance.
A judge who will oversee an upcoming hearing for approval of a $20 million settlement in a class action against Optus contractor BSA has urged the parties to sever the funder’s commission and costs from the settlement to avoid delays in distribution to group members.
Facebook owner Meta is fighting for broad non-publication orders in its battle with the ACCC over material it says could prejudice jury members in criminal proceedings by mining magnate Andrew Forrest.
Two Sydney roof tiling businesses have made admissions in civil penalty proceedings brought by the Australian Competition and Consumer Commission alleging they rigged bids for construction at the University of Sydney.
The Full Federal Court has rejected an Australian inventor’s appeal of a ruling that found three manufacturers of essential oil products did not infringe his patent because the oil was a “staple commercial product”.
Two insurers have won an appeal that blocks group members in a class action against sandalwood producer Quintis from receiving a further $11.25 million after a settlement was reached almost two years ago.
Viagogo has lost a bid to overturn a $7 million penalty handed down after a judge found the ticket reseller misled customers on an “industrial scale”.
Ford is seeking an extended hearing of its appeal from a class action judgment in favour of 185,000 vehicle owners over their allegedly defective cars, saying a “significant excavation” of the ruling is now in order.
Bayer has dropped its appeal to a ruling that quashed an extension for its patent covering an oral contraceptive, after the Full Court dealt drug makers a blow in two separate cases on how patent term extensions should be calculated.